medigraphic.com
ISSN 0187-5337 (Impreso)
Instituto Nacional de Perinatología

2005, Número 2

<< Anterior Siguiente >>

Perinatol Reprod Hum 2005; 19 (2)


Pruebas bioquímicas en sangre materna para la identificación de fetos con riesgo de defectos cromosómicos y complicaciones asociadas al embarazo

Gerulewicz-Vannini D, Hernández-Andrade E

Idioma: Español
Referencias bibliográficas: 70
Paginas: 106-117
Archivo PDF: 132.90 Kb.


RESUMEN

La determinación de marcadores bioquímicos en sangre materna en el primer y/o segundo trimestre del embarazo, permite seleccionar mujeres con un mayor riesgo de alteraciones cromosómicas fetales. Es aplicable a todas las embarazadas independientemente de su edad y al combinar sus resultados con los hallazgos de ultrasonido, la tasa de detección puede llegar a ser mayor de 70%. Estas pruebas aplicadas a mujeres mayores de 35 años disminuyen el número de procedimientos invasivos y el riesgo de pérdida para los fetos sanos. Los valores alterados de cada uno de estos marcadores, pueden también sugerir la existencia de otras patologías fetales, particularmente alteraciones estructurales, del riesgo de parto pretérmino o muerte fetal, así como del riesgo materno de desarrollar complicaciones inherentes al embarazo como la preeclampsia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Nicolaides KH. Screening for fetal chromosomal abnormalities: need to change the rules. Ultrasound Obstet Gynecol 1994; 4: 353-4.

  2. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886-94.

  3. Nikolic JA. Synthesis, structure and function of alpha-fetoproteins and their importance in medicine. Glas Srp Akad Nauka [Med] 1992; 42: 57-73.

  4. Sebire NJ, Spencer K, Noble PL, Hughes K, Nicolaides KH. Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1997; 104: 849-51.

  5. Goldberg I, Hod M, Katz I, Friedman S, Ovadia J. A case of hepatocellular carcinoma in pregnancy detected by routine screening of maternal alpha-fetoprotein. Acta Obstet Gynecol Scand 1991; 70(3): 241-2.

  6. Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den HM. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 2003; 189: 775-81.

  7. Chodirker BN, Greenberg CR, Giddins NG, Dawson AJ, Evans JA, Chudley AE. Low MSAFP levels and Williams syndrome. Am J Med Genet 1997; 72(4): 448-50.

  8. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984; 1(8383): 926-9.

  9. Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. New England Regional Genetics Group Prenatal Collaborative Study of Down Syndrome Screening. Am J Obstet Gynecol 1989; 160: 575-81.

  10. Jameson JL, Hollenberg AN. Regulation of chorionic gonadotropin gene expression. Endocr Rev 1993; 14: 203-21.

  11. Kato Y, Braunstein GD. Beta-core fragment is a major form of immunoreactive urinary chorionic gonadotropin in human pregnancy. J Clin Endocrinol Metab 1988; 66: 1197-201.

  12. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987; 7: 623-30.

  13. Petrocik E, Wassman ER, Kelly JC. Prenatal screening for Down syndrome with maternal serum human chorionic gonadotropin levels. Am J Obstet Gynecol 1989; 16: 1168-73.

  14. Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA et al. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990; 163 (4 Pt 1): 1248-53.

  15. Milunsky A, Nebiolo LM, Bellet D. Maternal serum screening for chromosome defects: human chorionic gonadotropin versus its free-beta subunit. Fetal Diagn Ther 1993; 8: 221-4.

  16. Norgaard-Pedersen B, Alfthan H, Arends J, Hogdall CK, Larsen SO, Pettersson K et al. A new simple and rapid dual assay for AFP and free beta hCG in screening for Down syndrome. Clin Genet 1994; 45: 1-4.

  17. Wenstrom KD, Owen J, Chu DC, Boots L. Free beta-hCG subunit versus intact hCG in Down syndrome screening. Obstet Gynecol 1997; 90: 370-4.

  18. Leuvering JH, Goverde BC, Thal PJ, Schuurs AH. A homogeneous sol particle immunoassay for human chorionic gonadotrophin using monoclonal antibodies. J Immunol Methods 1983; 60: 9-23.

  19. Cole LA, Shahabi S, Oz UA, Rinne KM, Omrani A, Bahado-Singh RO et al. Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG. Prenat Diagn 1999; 19: 351-9.

  20. Bahado-Singh RO, Oz U, Kovanci E, Cermik D, Flores D, Copel J et al. New triple screen test for Down syndrome: combined urine analytes and serum AFP. J Matern Fetal Med 1998; 7: 111-4.

  21. Bahado-Singh R, Oz U, Shahabi S, Omrani A, Mahoney M, Cole L. Urine hyper-glycosylated hCG plus ultrasound biometry for detection of Down syndrome in the second trimester in a high-risk population. Obstet Gynecol 2000; 95: 889-94.

  22. Cuckle HS, Canick JA, Kellner LH. Collaborative study of maternal urine beta-core human chorionic gonadotrophin screening for Down syndrome. Prenat Diagn 1999; 19: 911-7.

  23. Lee IS, Chung DY, Cole LA, Copel JA, Isozaki T, Hsu CD. Elevated serum nicked and urinary beta-core fragment hCG in preeclamptic pregnancies. Obstet Gynecol 1997; 90: 889-92.

  24. Lindberg BS, Johansson ED, Nilsson BA. Plasma levels of nonconjugated oestrone, oestradiol-17beta and oestriol during uncomplicated pregnancy. Acta Obstet Gynecol Scand Suppl 1974; 32: 21-36.

  25. Schleifer RA, Bradley LA, Richards DS. Ponting NR. Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening. Am J Obstet Gynecol 1995; 173: 1152-6.

  26. Newby D, Aitken DA, Howatson AG, Connor JM. Placental synthesis of oestriol in Down’s syndrome pregnancies. Placenta 2000; 21: 263-7.

  27. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum uncon-jugated oestriol in pregnancies with Down’s syndrome. Br J Obstet Gynaecol 1988; 95: 330-3.

  28. Wald NJ, Cuckle HS, Densem JW, Nan-chahal K, Canick JA, Haddow JE, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down’s syndrome. Br J Obstet Gynaecol 1988; 95: 334-41.

  29. Wallace EM, Riley SC, Crossley JA, Ritoe SC, Horne A, Shade M, et al. Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy. J Clin Endocrinol Metab 1997; 82: 218-22.

  30. Riley SC, Leask R, Balfour C, Brennand JE, Groome NP. Production of inhibin forms by the fetal membranes, decidua, placenta and fetus at parturition. Hum Reprod 2000; 15: 578-83.

  31. Wallace EM, Harkness LM, Burns S, Liston WA. Evaluation of maternal serum immunoreactive inhibin as a first trimester marker of Down’s syndrome. Clin Endo-crinol (Oxf) 1994; 41: 483-6.

  32. Van Lith JM, Pratt JJ, Beekhuis JR, Mantingh A. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down’s syndrome. Prenat Diagn 1992; 12: 801-6.

  33. Cuckle HS, Holding S, Jones R. Maternal serum inhibin levels in second-trimester Down’s syndrome pregnancies. Prenat Diagn 1994; 14: 387-90.

  34. Lambert-Messerlian GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down’s syndrome pregnancy. J Med Screen 1996; 3: 58-62.

  35. Spencer K, Wallace EM, Ritoe S. Second-trimester dimeric inhibin-A in Down’s syndrome screening. Prenat Diagn 1996; 16: 1101-10.

  36. Wallace EM, Swanston IA, McNeilly AS, Ashby JP, Blundell G, Calder AA, et al. Second trimester screening for Down’s syndrome using maternal serum dimeric inhibin A. Clin Endocrinol (Oxf) 1996; 44: 17-21.

  37. Wenstrom KD, Owen J, Chu DC, Boots L. Elevated second-trimester dimeric inhibin-A levels identify Down syndrome pregnancies. Am J Obstet Gynecol 1997; 177: 992-6.

  38. Sun IY, Overgaard MT, Oxvig C, Giudice LC. Pregnancy-associated plasma protein A proteolytic activity is associated with the human plancental trophoblast cell membrane. J Clin Endocrinol Metab 2002; 87: 5235-40.

  39. Bersinger NA, Groome N, Muttukrishna S. Pregnancy-associated and placental proteins in the placental tissue of normal pregnant women and patients with preeclampsia at term. Eur J Endocrinol 2002; 147: 785-93.

  40. Lin TM, Halbert SP, Spellacy WN, Berne BH. Plasma concentrations of four pregnancy proteins in complications of pregnancy. Am J Obstet Gynecol 1977; 128: 808-10.

  41. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 2002; 22: 778-82.

  42. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002; 87: 1762-67.

  43. Aitken DA, Ireland M, Berry E, Crossley JA, Macri JN, Burn J, et al. Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies. Prenat Diagn 1999; 19: 706-10.

  44. Spencer K, Tul N, Nicolaides KH. Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 2000; 20: 390-4.

  45. Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005; 192: 1761-7.

  46. Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 2004; 24: 774-80.

  47. Spencer K. Second trimester prenatal screening for Down’s syndrome using alpha-fetoprotein and free beta hCG: a seven-year review. Br J Obstet Gynaecol 1999; 106: 1287-93.

  48. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down’s syndrome. J Med Screen 1997; 4: 181-246.

  49. Goodburn SF, Yates JR, Raggatt PR, Carr C, Ferguson-Smith ME, Kershaw AJ, et al. Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme. Prenat Diagn 1994; 14: 391-402.

  50. Kellner LH, Weiner Z, Weiss RR, Neuer M, Martin GM, Mueenuddin M, et al. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study. Am J Obstet Gynecol 1995; 173: 1306-9.

  51. Huderer-Duric K, Skrablin S, Kuvacic I, Sonicki Z, Rubala D, Suchanek E. The triple-marker test in predicting fetal aneuploidy: a compromise between sensitivity and specificity. Eur J Obstet Gynecol Reprod Biol 2000; 88: 49-55.

  52. Palomaki GE, Haddow JE, Knight GJ, Wald NJ, Kennard A, Canick JA, et al. Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenat Dian 1995; 15: 713-23.

  53. Macri JN, Kasturi RV, Krantz DA, Cook EJ, Sunderji SG, Larsen JW. Maternal serum Down syndrome screening: unconjugated estriol is not useful. Am J Obstet Gynecol 1990; 162: 672-3.

  54. Evans MI, Chik L, O’Brien JE, Chin B, Dvorin E, Ayoub M, et al. MOMs (multiples of the median) and DADs (discriminant aneuploidy detection): improved specificity and cost-effectiveness of biochemical screening for aneuploidy with DADs. Am J Obstet Gynecol 1995; 172: 1138-47.

  55. David M, Merksamer R, Israel N, Dar H. Unconjugated estriol as maternal serum marker for the detection of Down syndrome pregnancies. Fetal Diagn Ther 1996; 11: 99-105.

  56. Kellner LH, Canick JA, Palomaki GE, Neveux LM, Saller DN, Jr., Walker RP et al. Levels of urinary beta-core fragment, total oestriol, and the ratio of the two in second-trimester screening for Down syndrome. Prenat Diagn 1997; 17: 1135-41.

  57. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down’s syndrome using maternal serum dimeric inhibin A. J Med Screen 1998; 5: 115-9.

  58. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down’s syndrome using inhibin-A as a serum marker. Prenat Diagn 1996; 16: 143-53.

  59. Benn PA, Fang M, Egan JF, Horne D, Collins R. Incorporation of inhibin-A in second-trimester screening for Down syndrome. Obstet Gynecol 2003; 101: 451-4.

  60. Benn PA. Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions. Clin Chim Acta 2002; 324: 1-11.

  61. Wenstrom KD, Owen J, Chu D, Boots L. Prospective evaluation of free beta-subunit of human chorionic gonadotropin and dimeric inhibin A for aneuploidy detection. Am J Obstet Gynecol 1999; 181: 887-92.

  62. Renier MA, Vereecken A, Van Herck E, Straetmans D, Ramaekers P, Buytaert P. Second trimester maternal dimeric inhibin-A in the multiple-marker screening test for Down’s syndrome. Hum Reprod 1998; 13: 744-8.

  63. Lam YH, Tang MH. Second-trimester maternal serum inhibin-A screening for fetal Down syndrome in Asian women. Prenat Diagn 1999; 19: 463-7.

  64. Lambert-Messerlian GM, Canick JA. Clinical application of inhibin-A measurement: prenatal serum screening for Down syndrome. Semin Reprod Med 2004; 22: 235-42.

  65. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down’s syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461-7.

  66. Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective BJOG 2004; 111: 521-31.

  67. Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective (double dagger). Semin Perinatol 2005; 29: 225-35.

  68. Maymon R, Bergman M, Segal S, Dreazen E, Weinraub Z, Herman A. Sequential first and second trimester screening tests: correlation of the markers’ levels in normal versus Down syndrome-affected pregnancies. Prenat Diagn 2001; 21: 1175-7.

  69. Canini S, Prefumo F, Famularo L, Venturini PL, Palazzese V, De Biasio P. Comparison of first trimester, second trimester and integrated Down’s syndrome screening results in unaffected pregnancies. Clin Chem Lab Med 2002; 40: 600-3.

  70. Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005; 25 (8): 645-52.




2020     |     www.medigraphic.com